文献速递神经肌肉病

优化抗髓鞘相关糖蛋白及IgM丙种球蛋白病检测以评估神经病治疗

Optimizing Anti-Myelin-Associated Glycoprotein and IgM-Gammopathy Testing for Neuropathy Treatment Evaluation.
PubMed 文献 · Neurology · 2024-11-05

研究纳入752例神经病患者,评估抗MAG滴定切点及IgM丙种球蛋白病检测对治疗评估的影响。典型抗MAG神经病最佳切点为≥10,000 BTU(敏感性74%,特异性100%),≥1,500 BTU可降低免疫可治性CIDP可能性。Mass-Fix较SPIEP额外检出IgM丙种球蛋白病,无MAG抗体的IgM丙种球蛋白病患者治疗反应较差。

要点

  • 典型抗MAG神经病最佳切点为≥10,000 BTU(敏感性74%,特异性100%)。
  • 抗MAG阴性(<1,500 BTU)且无IgM丙种球蛋白病与INCAT评分和summated CMAP改善相关。
  • 电生理确诊CIDP患者中,IgM丙种球蛋白病存在与更差治疗反应相关。

核心结论

  • 10,000 BTU切点似乎对典型抗MAG神经病最佳,而≥1,500 BTU可降低免疫可治性CIDP的可能性。
  • Mass-Fix提高了抗MAG及其他IgM丙种球蛋白病神经病中IgM丙种球蛋白病的检出。
  • 缺乏MAG抗体的IgM丙种球蛋白病患者显示治疗反应降低。

研究设计与样本

  • 研究纳入752例神经病患者(平均年龄63.8岁,女性31%),在30个月内识别。
  • 使用2021年欧洲神经病学学会/周围神经学会指南评估患者,采用抗MAG Bühlmann滴定单位(BTU)及Mass-Fix和血清蛋白免疫固定电泳检测IgM丙种球蛋白病。
  • 免疫治疗结局通过炎症性神经病病因和治疗(INCAT)及summated复合肌肉动作电位(CMAP)神经传导变化进行回顾。

主要发现

  • 患者分组:典型抗MAG神经病(n=104);非典型抗MAG神经病(n=13);远端或感觉为主型CIDP(n=25,其中7例无IgM丙种球蛋白病);典型CIDP(n=47,其中36例无IgM丙种球蛋白病);轴索性IgM丙种球蛋白病相关神经病(n=104);IgM丙种球蛋白病阴性、抗MAG阴性轴索性神经病(n=426);无神经病且抗MAG阴性(n=33)。
  • Mass-Fix在抗MAG抗体患者中额外检出4例IgM丙种球蛋白病(3%,4/117),在无抗MAG患者中额外检出7例(2%,7/376),均为SPIEP未检出。
  • 免疫治疗随访 available 于123例(平均23个月,范围3-120个月),包括47例CIDP(28例无IgM丙种球蛋白病)和76例非CIDP(5例无IgM丙种球蛋白病,45例抗MAG阳性)。
  • 治疗包括IVIG(n=89)、利妥昔单抗(n=80)和伊布替尼或泽布替尼(n=24)。
  • 典型抗MAG神经病最佳抗MAG阳性切点为≥1,500 BTU(敏感性78%,特异性96%)和≥10,000 BTU(敏感性74%,特异性100%)。

关键数值与推荐

  • 典型抗MAG神经病最佳抗MAG阳性切点:≥1,500 BTU(敏感性78%,特异性96%)和≥10,000 BTU(敏感性74%,特异性100%)。
  • 抗MAG阴性定义为<1,500 BTU。
  • IgM丙种球蛋白病检测方法:Mass-Fix(n=493)、SPIEP(n=355)或两者(n=96)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Patients with typical anti-myelin-associated glycoprotein (anti-MAG) neuropathy have IgM-gammopathy, mimic distal chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and are treatment resistant. Anti-MAG patients go unrecognized when IgM-gammopathy is undetected or with atypical phenotypes. We investigated an optimal anti-MAG titration cutoff for excluding CIDP and the impact of IgM-gammopathy detection on neuropathy treatment evaluation without anti-MAG antibodies. METHODS: European Academy of Neurology/Peripheral Nerve Society 2021 guidelines were used to assess patients with neuropathy using anti-MAG Bühlmann titration units (BTU) and IgM-gammopathy with Mass-Fix (mass spectrophotometry) and serum protein immunofixation electrophoresis (SPIEP). The immunotherapy outcome was reviewed by inflammatory neuropathy cause and treatment (INCAT) and summated compound muscle action potential (CMAP) nerve conduction changes. RESULTS: Seven hundred and fifty-two patients (average age: 63.8 years, female: 31%) were identified over 30 months: (1) typical anti-MAG neuropathy (n = 104); (2) atypical anti-MAG neuropathy (n = 13); (3) distal or sensory-predominant CIDP (n = 25), including 7 without IgM-gammopathy; (4) typical CIDP (n = 47), including 36 without IgM-gammopathy; (5) axonal IgM-gammopathy-associated neuropathy (n = 104); and (6) IgM-gammopathy-negative, anti-MAG-negative axonal neuropathies (n = 426); and (7) without neuropathy (n = 33) anti-MAG negative. IgM-gammopathy was evaluated by Mass-Fix (n = 493), SPIEP (n = 355), or both (n = 96). Mass-Fix detected 4 additional IgM-gammopathies (3%, 4/117) among patients with anti-MAG antibodies and 7 additional patients (2%, 7/376) without anti-MAG not detected by SPIEP testing. Immunotherapy follow-up was available in 123 (mean: 23 months, range: 3-120 months) including 47 with CIDP (28 without IgM-gammopathy) and 76 non-CIDP (5 without IgM-gammopathy, 45 anti-MAG positive). Treatments included IVIG (n = 89), rituximab (n = 80), and ibrutinib or zanubrutinib (n = 24). An optimal anti-MAG-positive cutoff was identified at ≥1,500 BTU (78% sensitivity, 96% specificity) and at ≥10,000 BTU (74% sensitivity, 100% specificity) for typical anti-MAG neuropathy. Improvements in INCAT scores (p < 0.0001) and summated CMAP (p = 0.0028) were associated with negative anti-MAG (<1,500 BTU, n = 78) and absence of IgM-gammopathy (n = 34). Among 47 patients with electrodiagnostically confirmed CIDP, all anti-MAG negative, the presence of IgM-gammopathy (n = 19) also correlated with a worse treatment response (INCAT scores p = 0.035, summated CMAP p = 0.049). DISCUSSION: A cutoff of 10,000 BTU seems optimal for typical anti-MAG neuropathy while ≥1,500 BTU reduces the likelihood of immune-treatable CIDP. Mass-Fix improves IgM-gammopathy detection in anti-MAG and other IgM-gammopathy neuropathies. Patients with IgM-gammopathy lacking MAG antibodies show reduced treatment response.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Klein CJ, Triplett JD, Murray DL, et al. Optimizing Anti-Myelin-Associated Glycoprotein and IgM-Gammopathy Testing for Neuropathy Treatment Evaluation. Neurology. 2024. PMID: 39499873. doi:10.1212/WNL.0000000000210000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。